Global Prostate Cancer Pipeline Review, H1 2018 - Therapeutic Assessment of 275 Companies - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 26, 2018--The “Prostate Cancer - Pipeline Review, H1 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Prostate Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 15, 118, 103, 7, 243, 34 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 10, 20, 58 and 21 molecules, respectively.
Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:Introduction Prostate Cancer - Overview Prostate Cancer - Therapeutics Development Prostate Cancer - Therapeutics Assessment Prostate Cancer - Companies Involved in Therapeutics Development Prostate Cancer - Drug Profiles Prostate Cancer - Discontinued Products Prostate Cancer - Product Development Milestones Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/vk4vbx/global_prostate?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180926006057/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Prostate Cancer Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/26/2018 05:17 PM/DISC: 09/26/2018 05:17 PM